Matching slides 303,780
Current window 216,271-216,300
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

216,271-216,300 of 303,780

filter-aware
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
14
Clinical trial baseline data table.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
16
HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis; HV = Healthy Volunteers; MAD = Multiple Ascending Dose; LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
17
The chart shows a clear reduction in IRAK4 protein levels in both AD and HS patient groups after 28 days of treatment, bringing them down to or below the baseline levels of healthy subjects.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
18
The slide compares cytokine inhibition efficacy in Healthy Subjects (MAD3), AD patients, and HS patients using two different stimulation methods (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
20
The slide uses individual patient data points (AD-1 to AD-7, HS-1 to HS-12) to show consistent downregulation across cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
21
Data presented as mean percentage change with standard error bars; N=7.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
25
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups. Includes error bars representing standard error of the mean or 80% confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
30
The table compares KT-474 (Part C) at Day 28 and 42 against external benchmarks at Week 4. Includes extensive footnote citations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
31
The footer explicitly notes the absence of Serious Adverse Events (SAEs), infections, or events leading to discontinuation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
33
The slide uses color-coded text (orange) to emphasize key positive outcomes within the bullet points.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
34
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
35
The diagram illustrates the signaling pathways (TLR, IL-1R, B Cell Receptor) and the specific points of intervention (red asterisks) for the therapy.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
37
The slide outlines a clinical trial design using a dose-escalation process leading to MTD/RP2D expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
38
Data presented for Cycle 1; DL4 shows mean values for n=2 patients.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
40
The slide uses a split-layout: left side focuses on clinical data (PK/PD/Safety), right side focuses on strategic positioning and clinical development plan.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
41
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
45
Clinical trial safety data table showing patient counts and percentages for specific adverse events.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
46
Includes a line chart for PK profiles and a table for PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
48
Includes bar charts for SAA/CRP reduction, a longitudinal line chart for biomarker changes, and a scatter plot showing correlation between STAT3 and SOCS3 changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit